Intimation of In-principle approval in matter of issue of 7,66,05,000 warrants convertible into equity shares on preferential basis received from BSE is attached herewith.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dipna Pharmachem has received BSE's in-principle approval to issue 7,66,05,000 (7.66 crore) warrants, each convertible into one equity share of Rs. 10 face value, to promoters and non-promoters on a preferential basis. The issue price is fixed at not less than Rs. 13.05 per warrant, which means a minimum potential capital raise of around Rs. 100 crore if all warrants are converted. The approval was granted on August 29, 2025, and the company must now complete allotment and file a listing application within 20 days of allotment. This is a significant equity dilution event relative to the company's size, and promoter participation signals some level of insider confidence.
Existing shareholders should expect meaningful equity dilution once the warrants are converted, though the funds raised could support growth. Promoter participation in the preferential issue is generally seen as a confidence signal, but the discounted-to-market nature of preferential allotments is often viewed unfavourably by retail investors.